Gene and cell therapy has crossed a remarkable threshold: the science genuinely works. There are now approved, sometimes one-time treatments for diseases that once meant lifelong suffering. The open question in 2026 is no longer whether these therapies can cure, but whether the business of making, delivering, and paying for them can be sustained. That tension shapes which companies are thriving and which are struggling. Here are the notable players, grouped by where they sit, along with the reality check the whole field is facing.
The commercial leaders with approved therapies
A group of companies has already brought advanced therapies to patients, and they are living the commercial reality of the field.
- Vertex Pharmaceuticals, with partner CRISPR Therapeutics, brought the first CRISPR-based medicine to market, a gene-edited cell therapy for sickle cell disease and beta-thalassemia, a genuine scientific landmark.
- Gilead’s Kite and Novartis are leaders in CAR-T cell therapy for blood cancers, though even these established products face pressure on growth as the market matures.
- Legend Biotech, partnered with Johnson & Johnson, has a fast-growing CAR-T therapy for multiple myeloma.
- Sarepta Therapeutics markets a gene therapy for Duchenne muscular dystrophy, and has navigated real safety and regulatory challenges in the process.
- Krystal Biotech stands out for turning an approved gene therapy for a rare skin disease into a genuinely profitable commercial business, a rarer feat in this field than the science alone.
The cautionary tale worth knowing
No survey of this field is honest without the story of bluebird bio, a company that helped define modern gene therapy, won approvals for multiple genetic diseases, and then hit a wall: brilliant science followed by a slow, expensive, operationally complex commercial rollout that the business could not sustain. It was taken private in 2025 and rebranded. Bluebird’s arc is the clearest illustration of the field’s central challenge, that curing a disease and building a viable business around the cure are two very different problems.
The gene-editing platform companies
A cluster of companies is advancing the next generation of genetic medicines built on precise editing.
- Intellia Therapeutics is a leader in in vivo CRISPR editing, aiming to edit genes directly inside the body rather than in the lab.
- Beam Therapeutics pioneers base editing, which rewrites individual DNA letters without cutting both strands, and Prime Medicine develops the even more versatile prime editing.
- CRISPR Therapeutics, beyond its approved therapy, has a broad pipeline, and Caribou Biosciences, Editas Medicine, and Precision BioSciences pursue their own editing approaches.
- A newer wave, including companies working on epigenetic editing (altering how genes are expressed without changing the DNA sequence), is pushing the frontier further still.
The reality check: a field under pressure
The counterweight to all this promise is a sobering business reality that intensified through 2025 and into 2026. Several large players have pulled back: one major pharma announced it would discontinue its cell therapy efforts and seek an external partner, and another moved to wind down its cell therapy activities entirely, affecting hundreds of employees. Even successful CAR-T products have seen growth slow. The reasons are structural: these therapies are expensive and operationally complex, they reach patients through a narrow network of specialized treatment centers, and they must be paid for by reimbursement systems built for chronic, repeat treatment rather than one-time cures. The science keeps delivering; the commercial and operational model is where the field is being tested.
What to look for in a gene or cell therapy company
Given that tension, evaluating these companies means looking beyond the science. The questions that matter are whether the company has a credible manufacturing strategy (a persistent bottleneck in the field), whether there is a realistic path to reimbursement and commercial viability for its therapies, whether it is financially strong enough to weather a long and expensive road (cash position is a genuine survival factor here), and whether its platform can produce more than a single product. The companies most likely to endure are the ones that pair genuine scientific edge with a clear-eyed plan for the operational and economic gauntlet that follows approval.
The bigger picture
Gene and cell therapy remains one of the most scientifically thrilling areas in all of medicine, and the long-term trajectory points toward more cures for more diseases. But 2026 is a year of maturation, when the field is being forced to solve the unglamorous problems of manufacturing, delivery, and payment that determine whether breakthrough science actually reaches patients at scale. This snapshot captures the notable players, but the landscape shifts constantly with new data, approvals, and, increasingly, retrenchments.
The access problem, up close
The single hardest problem in gene and cell therapy is not making the medicine; it is getting it to patients and getting paid for it. Because many of these therapies are one-time treatments with very high upfront prices, they collide with reimbursement systems designed for chronic drugs taken over years. A payer asked to pay a seven-figure sum in a single year for a therapy whose long-term benefit is still being proven has every incentive to hesitate, even when the treatment is genuinely curative. The industry is experimenting with creative solutions, including outcome-based agreements that tie payment to whether the therapy actually keeps working and arrangements that spread the cost over time, but these models are still maturing and add real operational complexity. Layered on top is the delivery bottleneck: many advanced therapies can only be administered at a limited network of specialized centers, which caps how many patients can realistically be treated even when demand exists.
A parallel technical race shapes the field’s future economics: the shift from autologous therapies, made individually from each patient’s own cells, toward allogeneic, or off-the-shelf, products made from donor cells that could in principle be manufactured at scale and stored ready to use. Autologous therapies have delivered remarkable results but are operationally punishing and expensive to produce one patient at a time; allogeneic approaches promise better economics and broader access if the science can be made to work reliably. Which model wins, and in which diseases, will do much to determine whether these breakthroughs reach large numbers of patients or remain constrained to a fortunate few. For anyone assessing a company in this space, its answers on manufacturing model, delivery, and reimbursement matter as much as its clinical data.
The investor’s view
For investors, gene and cell therapy is a field of dramatic swings, and understanding why helps make sense of the headlines. These companies often trade less on current revenue, which many do not yet have, than on the promise and progress of their science, so a single clinical readout, approval, or setback can move a company’s value sharply. The last couple of years have added a sobering dimension: the market has learned that scientific success does not guarantee commercial success, and it now scrutinizes the operational and economic questions, manufacturing, delivery, reimbursement, cash runway, as closely as the clinical data. That has made investors more discerning, rewarding companies that pair genuine scientific edge with a credible plan for the commercial gauntlet and punishing those that have breakthrough science but no clear path to a viable business. The result is a field where the biology is more proven than ever, yet the investment case increasingly hinges on the unglamorous questions of whether a company can actually make its therapy, get it to patients, and get paid. For anyone allocating capital here, the lesson of the recent cycle is to weight execution and economics as heavily as the science.
For the full, regularly updated map of gene and cell therapy companies, browse the BioMed Nexus gene and cell therapy directory, and to follow the approvals, readouts, and business developments reshaping the field, the daily brief covers it as it happens.
Frequently asked questions
What are the leading gene and cell therapy companies in 2026?
Commercial leaders include Vertex with CRISPR Therapeutics (the first CRISPR medicine), Gilead's Kite and Novartis in CAR-T, Legend Biotech, Sarepta and Krystal Biotech. Leading gene-editing platform companies include Intellia, Beam Therapeutics, Prime Medicine, CRISPR Therapeutics, Caribou, Editas and Precision BioSciences.
Why are some companies pulling back from cell and gene therapy?
Despite strong science, these therapies are expensive and operationally complex, reach patients only through specialized treatment centers, and must be paid for by reimbursement systems built for chronic care rather than one-time cures. These structural challenges have led some large players to discontinue or wind down cell therapy programs even as the underlying science advances.
How do I evaluate a gene or cell therapy company?
Look beyond the science to whether the company has a credible manufacturing strategy, a realistic path to reimbursement and commercial viability, enough cash to survive a long and expensive road, and a platform that can produce more than one product. In this field, operational and financial strength matter as much as scientific edge.
